Roche teams with Pieris in immuno-oncology; Roche intends to terminate deal
In its second immuno-oncology deal within days, Roche received worldwide rights to Pieris Pharmaceuticals Inc.'s Anticalin programs against an undisclosed cancer target. The agreement may be expanded to multiple targets.
- Large Molecule
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.